Title: Oligomeric Compounds and Compositions for Use in Modulation of Pri-miRNAs
Patent Number: 7,759,319
Filed: Jan. 10, 2006
Lead Inventor: Bridget Lollo, Regulus Therapeutics
The patent, its abstract states, claims "compounds, compositions, and methods … for modulating the levels, expression, processing, and function of pri-miRNAs. In particular, methods and compounds are provided for the modulation of the levels, expression, processing, or function of polycistronic pri-miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and pri-miRNAs.
"Further provided are methods for selectively modulating pri-miRNA levels in a cell," the abstract adds. "Also provided are methods for identifying oligomeric compounds that result in increased pri-miRNA levels when contacted with a cell."
Title: Compositions and Methods for Inhibiting Gene Expression of a Gene from the Ebola
Patent Number: 7,759,320
Filed: March 25, 2008
Lead Inventor: Sina Bavari, Alnylam Pharmaceuticals
"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the Ebola virus," the patent's abstract states.
Title: RNA Interference Pathway Genes as Tools for Targeted Genetic Interference
Patent Number: 7,759,463
Filed: Feb. 22, 2007
Lead Inventor: Craig Mello, University of Massachusetts
"Genes involved in double-stranded RNA interference are identified and used to investigate the RNAi pathway," according to the patent's abstract. "The genes and their products are also useful for modulating RNAi pathway activity."
Title: Bioinformatically Detectable Viral Regulatory Genes
Patent Number: 7,759,478
Filed: Aug. 29, 2003
Inventor: Isaac Bentwich, Rosetta Genomics
The invention, the patent's abstract states, "relates to a group of novel viral RNA regulatory genes, here identified as viral genomic address messenger genes or VGAM genes, and as genomic record or GR genes.
"VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism," it states. "GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing, and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity."
Title: Modified iRNA Agents
Patent Number: 20100179309
Filed: Nov. 16, 2009
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
"The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose," the patent application's abstract states. "The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, [for instance] by using the non-ribose moiety as a point to which a ligand or other entity … optionally substituted with at least one carbohydrate [and] directly or indirectly tethered. The invention also relates to methods of making and using such modified iRNA agents."